AUS
NZ
UK
CA
USA
IND
Highlights
- Immuron (ASX:IMC) supports US military research on a new treatment for enteric diseases.
- Interim trial results show limited protective efficacy against Campylobacter.
- The trial does not affect Immuron's plans for Travelan® or its FDA meeting.
Immuron Ltd (ASX:IMC), a globally integrated biopharmaceutical company, has made significant strides in developing new therapeutics targeting enteric diseases like Campylobacter and Enterotoxigenic Escherichia coli (ETEC). These efforts are part of a broader study conducted by the US Naval Medical Research Command (NMRC), aimed at finding new solutions for combatting infectious diarrheal diseases, a high priority for the US military. ASX healthcare stocks are closely watching developments in this area, as advancements could have significant implications for the sector.
Focus on a New Vaccine
The NMRC, backed by the US Department of Defense, is actively working on vaccines targeting various pathogens, including Campylobacter, Shigella, and different strains of E. coli. One of the main goals is to create a treatment that can prevent enteric diseases, which are common among military personnel deployed overseas.
Immuron's role in this study involves producing a hyperimmune bovine colostrum product. This product, developed using a vaccine created by the NMRC, was tested in a controlled human infection model. The Campylobacter jejuni pathogen is a leading cause of diarrheal disease worldwide, yet no licensed vaccine currently exists.
Promising Trial Results
The trial results so far show that the hyperimmune product developed by Immuron using the NMRC vaccine produced a strong immunological response in cows. The new therapeutic contains high levels of antibodies specifically targeting the Campylobacter jejuni capsule and the colonization factor antigen of ETEC.
A group of 27 volunteers participated in the study, and the interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis when compared to the placebo group. The NMRC is continuing to evaluate the data to understand the lower efficacy, particularly compared to other studies involving Travelan®, Immuron’s flagship product.
Impact on Immuron's Strategy
The results of this trial do not impact Immuron's existing plans for Travelan®. Immuron continues to focus on advancing Travelan® to the next phase of its development. The company is preparing for an end of Phase 2 meeting with the US Food and Drug Administration (FDA), with plans to begin Phase 3 clinical trials in the second half of next year.
Additionally, the trial has no bearing on Immuron's commercial strategy for Travelan®, which remains focused on the results of a separate clinical study funded by the Uniformed Services University. This study, with 85% of participants already recruited, aims to provide topline results by April 2025.
Travelan® and Combatting Infectious Diarrhoea
Travelan® has already demonstrated efficacy in preventing ETEC-related diarrhoea in previous studies. The product has shown protection rates ranging from 76.7% to 90.9% in various dosing regimens. The development of additional hyperimmune products, designed to specifically target individual pathogens, is part of Immuron's ongoing collaboration with the NMRC.
Diarrheal diseases remain a significant challenge for travelers and military personnel, often leading to a decline in daily performance and operational readiness. With rising resistance to antibiotics, new preventative treatments like those being developed by Immuron are essential for addressing the global burden of these infections.
